Alleviating cancer drug toxicity by inhibiting a bacterial enzyme

Bret D. Wallace, Hongwei Wang, Kimberly T. Lane, John E. Scott, Jillian Orans, Ja Seol Koo, Madhukumar Venkatesh, Christian Jobin, Li An Yeh, Sridhar Mani, Matthew R. Redinbo

Research output: Contribution to journalArticle

343 Citations (Scopus)

Abstract

The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)831-835
Number of pages5
JournalScience
Volume330
Issue number6005
DOIs
StatePublished - Nov 5 2010

Fingerprint

irinotecan
Drug-Related Side Effects and Adverse Reactions
Glucuronidase
Enzymes
Neoplasms
Bacteria
Aerobic Bacteria
Anaerobic Bacteria
Pharmaceutical Preparations
Colonic Neoplasms
Oral Administration
Diarrhea
Health

ASJC Scopus subject areas

  • General

Cite this

Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., ... Redinbo, M. R. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science, 330(6005), 831-835. https://doi.org/10.1126/science.1191175

Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. / Wallace, Bret D.; Wang, Hongwei; Lane, Kimberly T.; Scott, John E.; Orans, Jillian; Koo, Ja Seol; Venkatesh, Madhukumar; Jobin, Christian; Yeh, Li An; Mani, Sridhar; Redinbo, Matthew R.

In: Science, Vol. 330, No. 6005, 05.11.2010, p. 831-835.

Research output: Contribution to journalArticle

Wallace, BD, Wang, H, Lane, KT, Scott, JE, Orans, J, Koo, JS, Venkatesh, M, Jobin, C, Yeh, LA, Mani, S & Redinbo, MR 2010, 'Alleviating cancer drug toxicity by inhibiting a bacterial enzyme', Science, vol. 330, no. 6005, pp. 831-835. https://doi.org/10.1126/science.1191175
Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010 Nov 5;330(6005):831-835. https://doi.org/10.1126/science.1191175
Wallace, Bret D. ; Wang, Hongwei ; Lane, Kimberly T. ; Scott, John E. ; Orans, Jillian ; Koo, Ja Seol ; Venkatesh, Madhukumar ; Jobin, Christian ; Yeh, Li An ; Mani, Sridhar ; Redinbo, Matthew R. / Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. In: Science. 2010 ; Vol. 330, No. 6005. pp. 831-835.
@article{9eceb0e24c364bd2a3dcbdb188d57026,
title = "Alleviating cancer drug toxicity by inhibiting a bacterial enzyme",
abstract = "The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.",
author = "Wallace, {Bret D.} and Hongwei Wang and Lane, {Kimberly T.} and Scott, {John E.} and Jillian Orans and Koo, {Ja Seol} and Madhukumar Venkatesh and Christian Jobin and Yeh, {Li An} and Sridhar Mani and Redinbo, {Matthew R.}",
year = "2010",
month = "11",
day = "5",
doi = "10.1126/science.1191175",
language = "English (US)",
volume = "330",
pages = "831--835",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6005",

}

TY - JOUR

T1 - Alleviating cancer drug toxicity by inhibiting a bacterial enzyme

AU - Wallace, Bret D.

AU - Wang, Hongwei

AU - Lane, Kimberly T.

AU - Scott, John E.

AU - Orans, Jillian

AU - Koo, Ja Seol

AU - Venkatesh, Madhukumar

AU - Jobin, Christian

AU - Yeh, Li An

AU - Mani, Sridhar

AU - Redinbo, Matthew R.

PY - 2010/11/5

Y1 - 2010/11/5

N2 - The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.

AB - The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential for human health. Potent bacterial β-glucuronidase inhibitors were identified by high-throughput screening and shown to have no effect on the orthologous mammalian enzyme. Crystal structures established that selectivity was based on a loop unique to bacterial β-glucuronidases. Inhibitors were highly effective against the enzyme target in living aerobic and anaerobic bacteria, but did not kill the bacteria or harm mammalian cells. Finally, oral administration of an inhibitor protected mice from CPT-11-induced toxicity. Thus, drugs may be designed to inhibit undesirable enzyme activities in essential microbial symbiotes to enhance chemotherapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=78149295964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149295964&partnerID=8YFLogxK

U2 - 10.1126/science.1191175

DO - 10.1126/science.1191175

M3 - Article

C2 - 21051639

AN - SCOPUS:78149295964

VL - 330

SP - 831

EP - 835

JO - Science

JF - Science

SN - 0036-8075

IS - 6005

ER -